Geron Corporation (GON.F)
| Previous close | 3.4940 |
| Open | 3.8450 |
| Bid | 3.7240 x 200000 |
| Ask | 3.7510 x 200000 |
| Day's range | 3.8450 - 3.8450 |
| 52-week range | 1.5810 - 3.8450 |
| Volume | |
| Avg. volume | 694 |
| Market cap | 2.264B |
| Beta (5Y monthly) | 0.61 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Geron Corporation (NASDAQ:GERN) Is Expected To Breakeven In The Near Future
We feel now is a pretty good time to analyse Geron Corporation's ( NASDAQ:GERN ) business as it appears the company may...
- Zacks
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.
- Yahoo Finance Video
Geron, Madrigal Pharmaceuticals jump on good news from FDA
Shares of both Geron (GERN) and Madrigal Pharmaceuticals (MDGL) are soaring after receiving positive news from the Food and Drug Administration. For Geron, an FDA advisory panel backed its blood disorder treatment. For Madrigal, the FDA approved its treatment for a liver disease known as nonalcoholic steatohepatitis, or NASH. Yahoo Finance's Josh Lipton and Julie Hyman discuss the stocks' reaction in the video above. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Stephanie Mikulich.
